

Predictive Markers of Coagulopathy in COVID-19 Infection: A Meta Narrative Review

Arili Bedoy*, Adriana Chapa*, Jose Enriquez*, Christy Saquin*, Uyen Tran*, Ashley Trevizo*, Kimberly Hoggatt Krumwiede, Ph.D., Mary Coolbaugh-Murphy, Ph.D., MB(ASCP)^{CM}, Denise M. Juroske Short, Ph.D., MB(ASCP)^{CM} Clinical Laboratory Science, School of Health Professions, UT MD Anderson Cancer Center

* Authors contributed equally and are listed in alphabetical order

Introduction

In late 2019, COVID was initially discovered in Wuhan, China, and the COVID-19 pandemic primarily began in early 2020. Along with respiratory distress, COVID-19 patients have an increased risk of the formation of abnormal clotting. In ICU COVID-19 patients, abnormal clotting increases the risk of mortality by around 74% (Montiel et al., 2022).

By determining predictive markers of coagulopathy in COVID-19 infection, severe cases of COVID-19 can be identified before bleeding and thrombotic manifestations occur and future research can better identify prophylactic measures that can be taken to prevent clotting events. As a result, the prognoses of those with severe COVID-19 infection may be improved.

Guiding Research Question

What hemostatic parameters are predictive of coagulopathy in COVID-19 patients?

Methodology

Identification Total number of articles identified through database searching based on selection criteria "Covid AND bleeding" (n=226) "Covid AND coagulation" (n=285) "Covid AND abnormal clotting" (n=22) "Pandemic coagulation" (n=93) "Pandemic clotting" (n=48) Total n=674



Figure 1. Article Screening Flow Diagram

Figure 2. Predictive Markers and Signs of Coagulopathy in COVID-19 Infection



Table 1. Article Key Findings

Authors	Year	Key Findings
Al-Samkari et al.	2020	 Overall thrombotic complication rate Overall bleeding rate was 4.8% Elevated D-dimer levels predicted
Fan et al.	2020	 Elevated FVIII, vWF, D-dimer, and associated with the hypercoagula
Gardiner et al.	2022	 sTM, vWF were significantly highe Endothelial dysfunction plays in in
Luo et al.	2020	 Coagulation parameters such as I severe COVID patients
Montiel et al.	2022	 Endothelial oxidative stress leadir COVID coagulopathy
Nikolaidis et al.	2021	 Decreased nitric oxide correspond
Dayna Nguyen, Hey- Min Jeon, Jeongwu Lee	2022	 Upregulation of F3 in lung epitheli

Selection Criteria

Database: PubMed, NIH, CDC, The Lancet **Search Terms**: "COVID and bleeding", "COVID and coagulation', "COVID and abnormal clotting", "pandemic coagulation", "pandemic clotting", "COVID related deaths"

Dates of Coverage: 2020 - 2023 **Type of Research**: Primary

the markers.





Making Cancer History[®]

Conclusion

Common biomarkers with highly predictive capabilities for hypercoagulability were identified within the 7 articles.

The most common predictive hemostatic parameters identified were:

- Elevated FVIII
- Elevated Von Willebrand Factor (vWF) Elevated D-dimer
- Decreased fibrinogen

The common biomarkers could be used for early detection or determination of worsening condition so that early antithrombotic treatment can be administered.

Future Research

Most articles focused on elevated D-dimer as an early marker of coagulopathy in COVID-19 patients. However, according to Gardiner et al. (2022), soluble thrombomodulin (sTM) proved to be the best predictor in their study. Other tests and values, such as clot waveform analysis (CWA), were noted as potential options for routine monitoring in ICU COVID-19 patients. However, further testing outside the scope of this review is necessary to determine the validity of their usage.

References

- Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., Leaf, D. E., Kuter, D. J., & Rosovsky, R. P. (2020). Covid-19 and coagulation: Bleeding and thrombotic manifestations of SARS-COV-2 infection. *Blood*, *136*(4), 489–500.
 - https://doi.org/10.1182/blood.2020006520
- Fan, B. E., Ng, J., Chan, S. S. W., Christopher, D., Tso, A. C. Y., Ling, L. M., Young, B. E., Wong, L. J. L., Sum, C. L. L., Tan, H. T., Ang, M. K., Lim, G. H., Ong, K. H., Kuperan, P., & Chia, Y. W. (2021). COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. Journal of thrombosis and thrombolysis, 51(3), 663–674. https://doi-
- org.elibrary.mdanderson.org/10.1007/s11239-020-02318-x Gardiner, C., Mackie, I. J., MacCallum, P., & amp; Platton, S. (2022). Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (covid-19) patients. International Journal of Laboratory Hematology, 44(5), 817–822. https://doi.org/10.1111/ijlh.13855
- Luo, H. C., You, C. Y., Lu, S. W., & Fu, Y. Q. (2021). Characteristics of coagulation alteration in patients with COVID-19. Annals of hematology, 100(1), 45–52. https://doi-org.elibrary.mdanderson.org/10.1007/s00277-<u>020-04305-x</u>
- Montiel, V., Lobysheva, I., Gérard, L., Vermeersch, M., Perez-Morga, D., Castelein, T., Mesland, J. B., Hantson, P., Collienne, C., Gruson, D., van Dievoet, M. A., Persu, A., Beauloye, C., Dechamps, M., Belkhir, L., Robert, A., Derive, M., Laterre, P. F., Danser, A. H. J., Wittebole, X., Balligand, J. L. (2022). Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. *EBioMedicine*, 77, 103893. https://doi-org.elibrary.mdanderson.org/10.1016/j.ebiom.2022.103893
- Nguyen, D., Jeon, H. M., & Lee, J. (2022). Tissue factor links inflammation, thrombosis, and senescence in COVID-19. *Scientific reports*, 12(1), 19842. https://doi.org/10.1038/s41598-022-23950-y
- Nikolaidis, A., Kramer, R., & Ostojic, S. (2021). Nitric Oxide: The Missing Factor in COVID-19 Severity?. Medical sciences (Basel, Switzerland), 10(1), 3. https://doi.org/10.3390/medsci10010003